Vertex Pharmaceuticals (VRTX)
$480.35
1.30 (0.27%)
VRTX Stock Quote Delayed 30 Minutes
3 Biotech Stocks to Buy on the Dip: August 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
124.62B
PE Ratio
-221.36
EPS
-2.17
Volume (Avg. Vol.)
1.20M
Day's Range
$476.26 - $486.14
52-Week Range
$377.85 - $519.88
Dividend & Yield
N/A (N/A)
VRTX Stock Predictions, Articles, and Vertex Pharmaceuticals News
The Top 3 Biotech Stocks to Buy Now Summer 2024
These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects.
7 Biotech Stocks to Keep on Your Clinical Radar
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.
3 Gene Editing Stocks Shaping the Future of Medicine
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions
The 3 Best Neuroscience Biotech Stocks to Buy Now
Given the high bar to developing good neuroscience drugs, firms that do so will likely succeed. Here are three top biotech stocks to buy now.
3 Gene Editing Stocks That Could Grow Your Wealth
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks.
3 Pharma Stocks Already Ushering in the Next Biotech Boom
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.
The 3 Best Biotech Stocks to Buy in July 2024
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024.
3 Top-Rated Gene Editing Stocks Actually Making Money
Profitable gene editing stocks make increasingly compelling investments as therapies commercialize this year and beyond.
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three.
3 Breakout Biotech Stocks on Track to Double by 2032
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify.
3 Biotech Stocks That Could Make Your Grandchildren Rich
These biotech stocks are poised to generate significant returns to investors due to their high growth potential.
VRTX Stock Earnings: Vertex Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
VRTX stock results show that Vertex Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
